Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8, 2024, at 4:15 p.m. ET.
Can-Fite生物醫藥有限公司(NYSE American: CANF)(TASE: CFBI)是一家生物技術公司,正在推進一系列專有小分子藥物的管線,以解決腫瘤和炎症性疾病,邀請投資者於2024年8月8日美國東部時間下午4:15參加網絡研討會。
The exclusive event, hosted by RedChip Companies, will feature Can-Fite Chief Executive Officer Motti Farbstein and Executive Chairperson and Chief Scientific Officer Dr. Pnina Fishman, who will share insight into the Company's current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets, Can-Fite is targeting unmet medical needs in markets with a combined value in excess of $70 billion.
這次獨家活動由RedChip企業主辦,將邀請Can-Fite的首席執行官Motti Farbstein和常務主席兼首席科學官Dr. Pnina Fishman分享公司當前的高效價值管線和即將到來的重大項目。Can-Fite已經與多個外部許可交易和潛在里程碑付款策略定位。總計超過1.3億美金。Can-Fite已獲得了2,000萬美金的前期和里程碑付款,突顯其療法的潛力。Can-Fite擁有先進的資產,在市場上針對價值超過700億美金的未滿足的醫療需求。
To register for the free webinar, please visit:
要註冊免費的網絡研討會,請訪問:
Questions can be pre-submitted to CANF@redchip.com or online during the live event.
可以預先在CANT@redchip.com或在現場活動期間在線提交問題。
About Can-Fite BioPharma Ltd.
關於Can-Fite生物醫藥有限公司。
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: .
Can-Fite生物醫藥有限公司(NYSE American: CANF)(TASE: CANF)是一家擁有平台技術的先進臨床階段藥物開發公司,旨在解決治療癌症、肝臟和炎症性疾病市場的多十億美金市場。公司的主導藥物候選藥物,Piclidenoson最近在治療牛皮癬的第III期試驗中報告了頭號結果,並有望開始至關重要的第III期。Can-Fite的癌症和肝臟藥物Namodenoson正在進行IIb期試驗,以治療代謝紊亂相關脂肪肝(MASH),重點關注的是肝細胞癌(HCC)的至關重要試驗,並計劃在胰腺癌中進行IIa期研究。Namodenoson已獲得美國和歐洲的孤兒藥物認證,美國食品和藥物管理局授予其快速行動認證,用作HCC的二線治療。Namodenoson還顯示出潛在地治療其他癌症,包括結腸癌、前列腺癌和黑色素瘤。公司的第三個藥物候選藥物CF602在治療勃起功能障礙方面效果顯著。這些藥物在迄今爲止的臨床研究中有超過1600名患者的經驗,並且具有出色的安全性能。欲知更多信息請訪問:。
Forward-Looking Statements
前瞻性聲明
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite's Annual Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
本新聞稿可能包含關於Can-Fite所期望、信奉或打算的前瞻性聲明,涉及產品開發努力、業務、財務狀況、經營業績、戰略或前景等方面的內容。此處的所有聲明都是“前瞻性聲明”,並非公司歷史事實的關聯。前瞻性聲明可以通過使用前瞻性語言,例如“相信”、“期望”、“打算”、“計劃”、“可能”、“應該”或“預期”或它們的否定或這些詞或其他可比較的詞的變體來確定,並非嚴格與歷史或當前事實相關的陳述。前瞻性聲明涉及到作爲它們做出日期的預期或預期的事件、活動、趨勢或結果。由於前瞻性聲明涉及到尚未發生的事項,這些聲明本質上承擔着已知和未知的風險、不確定性和其他因素,這些因素可能導致Can-Fite的實際結果、業績或成就與任何未來結果、業績或成就在前瞻性聲明中表現的結果、業績或成就本質上不同。這些風險、不確定性和其他因素的重要因素包括我們的虧損歷史和需要額外資金來資助經營活動和我們無法獲得任何資本的需要或不能獲得接受的條款或完全沒有額外資本;現金流和無法滿足營運需求的不確定性;我們的臨床前研究、臨床試驗和其他產品候選開發努力的啓動、時間、進展和結果;我們能夠將我們的產品候選進入臨床試驗或成功完成我們的臨床前研究或臨床試驗的能力;我們的產品候選在獲得監管批准和其他監管申請和批准的時間;我們的產品候選的臨床開發、商業化和市場接受度;我們能夠建立和維護戰略伙伴關係和其他公司企業合作關係;我們的商業模式和企業和產品候選的戰略計劃的實施;我們能夠爲涵蓋我們的產品候選的知識產權權利建立和維護範圍,並在不侵犯他人知識產權權利的情況下運作我們的業務;我們行業內的競爭公司、技術和;與COVID-19大流行的復甦和以色列與哈馬斯之間的戰爭有關的風險;與無法滿足紐約證券交易所美國公司持續上市要求的風險有關;以及有關以色列政治和安全形勢對我們業務的影響的聲明。更多關於這些風險、不確定性和其他因素的信息包括Can-Fite關於2024年3月28日提交給美國證券交易委員會的20-F年度報告以及向TASE提交的其他公開報告中的“風險因素”部分和其定期提交文件中。現有和潛在的投資者被告知不要過分依賴這些前瞻性聲明,這些前瞻性聲明僅作本新聞稿發出之日的陳述。Can-Fite不承擔公開更新或複審任何前瞻性陳述的義務,無論是因爲新信息、未來發展或其他原因,除非任何適用證券法律所要求的。
Contacts
聯繫方式
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
can-fite biopharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Dave Gentry
RedChip Companies, Inc.
CANF@redchip.com
1-407-644-4256
Dave Gentry
RedChip Companies, Inc.
CANT@redchip.com
1-407-644-4256